Cellular Biomedicine Group Inc. (CBMG) 20.12 $CBMG
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Fri Aug 15, 9:00AM CDT
What:
Cellular Biomedicine Group Reports Second Quarter and First Half 2014 Financial Results and Provides Business Highlights
GlobeNewswire - Thu Aug 14, 10:58AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today reported financial results for the three and six months ended June 30, 2014 and provided business highlights including the six-month data from its Phase I/IIa clinical trial for ReJoin treatment for Knee Osteoarthritis (KOA).
Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Tue Aug 12, 8:02AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that it has treated the final patient in its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).
Cellular Biomedicine Group to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that the Company will ring The NASDAQ Stock Market Closing Bell on Monday, August 18, 2014 at 4:00 P.M. EDT. A live webcast will be available at https://new.livestream.com/nasdaq/live.
Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology and U.S. Patent
GlobeNewswire - Mon Aug 04, 8:16AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced reaching an agreement to acquire Agreen Biotech Co. Ltd. China ("AG" and its founder's U.S. patent for a total cash and equity consideration of $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.
Cellular Biomedicine Group Announces Discontinuation of Consulting Business Segment
GlobeNewswire - Mon Jun 30, 8:05AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the discontinuation of the Company's consulting business segment. The consulting business is expected to be classified as discontinued operations, effective July 1, 2014.
Cellular Biomedicine Group Completes Enrollment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Thu Jun 26, 7:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).
Cellular Biomedicine Group Announces Closing of $10 Million Private Placement Offering
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the closing of a private placement transaction under which it sold an aggregate of 1,492,537 shares (the "Shares" of the Company's common stock, par value $0.001 per share (the "Common Stock" , to selected private investors (the "Investors" at $6.70 per share, for total gross proceeds of approximately $10 Million.
Cellular Biomedicine Group Releases Positive Six-Month Data From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Thu Jun 19, 7:30AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) today released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin(TM) human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.
Cellular Biomedicine Group Commences Trading of Its Common Stock on The NASDAQ Capital Market
GlobeNewswire - Wed Jun 18, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock commences trading on NASDAQ under the ticker symbol "CBMG" effective today, June 18, 2014.
Cellular Biomedicine Group Approved for Listing on the NASDAQ Capital Market
GlobeNewswire - Mon Jun 16, 7:00AM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "CBMG" on June 18, 2014. The Company's common stock will continue to trade as "CBMG" on the OTCQB until the market closes on June 17, 2014.
Cellular Biomedicine Group Releases Positive Results From Phase I Clinical Trial for Hepatocellular Carcinoma
GlobeNewswire - Mon Mar 24, 11:53AM CDT
Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce positive results from its Phase I clinical trial, which evaluated the safety of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell Therapy
GlobeNewswire - Mon Mar 17, 12:28PM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma.
Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Mon Feb 24, 10:15AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe.
Cellular Biomedicine Group to Present at New York Stem Cell Summit
GlobeNewswire - Wed Feb 05, 6:24PM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.
Cellular Biomedicine Group Announces Appointment of New Chief Financial Officer and Board Secretary and New Audit Committee Chair
GlobeNewswire - Fri Jan 03, 11:45AM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG.
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Fri Dec 13, 2:33PM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group Announces Change of Auditor
PR Newswire - Wed Sep 11, 8:28AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO" as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC" .
Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Sep 06, 6:00AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.
Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Thu Aug 22, 10:48AM CDT
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Fri Aug 15, 9:00AM CDT
What:
Cellular Biomedicine Group Reports Second Quarter and First Half 2014 Financial Results and Provides Business Highlights
GlobeNewswire - Thu Aug 14, 10:58AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today reported financial results for the three and six months ended June 30, 2014 and provided business highlights including the six-month data from its Phase I/IIa clinical trial for ReJoin treatment for Knee Osteoarthritis (KOA). Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Tue Aug 12, 8:02AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
today announced that it has treated the final patient in its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA). Cellular Biomedicine Group to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
today announced that the Company will ring The NASDAQ Stock Market Closing Bell on Monday, August 18, 2014 at 4:00 P.M. EDT. A live webcast will be available at https://new.livestream.com/nasdaq/live. Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology and U.S. Patent
GlobeNewswire - Mon Aug 04, 8:16AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced reaching an agreement to acquire Agreen Biotech Co. Ltd. China ("AG" and its founder's U.S. patent for a total cash and equity consideration of $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units. Cellular Biomedicine Group Announces Discontinuation of Consulting Business Segment
GlobeNewswire - Mon Jun 30, 8:05AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the discontinuation of the Company's consulting business segment. The consulting business is expected to be classified as discontinued operations, effective July 1, 2014. Cellular Biomedicine Group Completes Enrollment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Thu Jun 26, 7:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA). Cellular Biomedicine Group Announces Closing of $10 Million Private Placement Offering
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) (the "Company"
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the closing of a private placement transaction under which it sold an aggregate of 1,492,537 shares (the "Shares" of the Company's common stock, par value $0.001 per share (the "Common Stock" , to selected private investors (the "Investors" at $6.70 per share, for total gross proceeds of approximately $10 Million. Cellular Biomedicine Group Releases Positive Six-Month Data From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Thu Jun 19, 7:30AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) today released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin(TM) human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.
Cellular Biomedicine Group Commences Trading of Its Common Stock on The NASDAQ Capital Market
GlobeNewswire - Wed Jun 18, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock commences trading on NASDAQ under the ticker symbol "CBMG" effective today, June 18, 2014. Cellular Biomedicine Group Approved for Listing on the NASDAQ Capital Market
GlobeNewswire - Mon Jun 16, 7:00AM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG) (the "Company"
, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "CBMG" on June 18, 2014. The Company's common stock will continue to trade as "CBMG" on the OTCQB until the market closes on June 17, 2014. Cellular Biomedicine Group Releases Positive Results From Phase I Clinical Trial for Hepatocellular Carcinoma
GlobeNewswire - Mon Mar 24, 11:53AM CDT
Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce positive results from its Phase I clinical trial, which evaluated the safety of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell Therapy
GlobeNewswire - Mon Mar 17, 12:28PM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma.
Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Mon Feb 24, 10:15AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe.
Cellular Biomedicine Group to Present at New York Stem Cell Summit
GlobeNewswire - Wed Feb 05, 6:24PM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.
Cellular Biomedicine Group Announces Appointment of New Chief Financial Officer and Board Secretary and New Audit Committee Chair
GlobeNewswire - Fri Jan 03, 11:45AM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG.
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Fri Dec 13, 2:33PM CST
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
Cellular Biomedicine Group Announces Change of Auditor
PR Newswire - Wed Sep 11, 8:28AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO"
as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC" . Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Sep 06, 6:00AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.
Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
PR Newswire - Thu Aug 22, 10:48AM CDT
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.
